For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Placebo + Lifestyle Therapy | Placebo in combination with behavioral diet to induce \~10% weight loss and supervised aerobic and exercise training Lifestyle Therapy: Weekly behavioral diet to induce \~10% weight loss in combination with supervised aerobic and exercise training three times a week Placebo: Placebo gel for testosterone | 0 | None | 1 | 41 | 12 | 41 | View |
| Testosterone + Lifestyle Therapy | Testosterone replacement in combination with behavioral diet to induce \~10% weight loss + supervised aerobic and exercise training Testosterone: Daily testosterone gel applied once daily in the morning to intact skin Lifestyle Therapy: Weekly behavioral diet to induce \~10% weight loss in combination with supervised aerobic and exercise training three times a week | 0 | None | 1 | 42 | 6 | 42 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Congestive heart failure | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Cardiac arrest | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Pulmonary embolism | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | None | View |
| Bleeding peptic ulcer | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Cellulitis | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| Ankle fracture | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | None | View |
| Idiopathic thrombocytopenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Intestinal obstruction | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Duodenitis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Acute kidney injury | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Hyperosmolar hyperglycemic state | SYSTEMATIC_ASSESSMENT | Endocrine disorders | None | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| hypoglycemia, asymptomatic and symptomatic | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | None | View |
| Dizziness/orthostasis | SYSTEMATIC_ASSESSMENT | Vascular disorders | None | View |
| Elevated PSA | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | None | View |